Suppr超能文献

巨噬细胞利用自身的钙网蛋白作为导向吞噬癌细胞:Toll样受体(TLR)和布鲁顿酪氨酸激酶(Btk)的作用

Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk.

作者信息

Feng Mingye, Chen James Y, Weissman-Tsukamoto Rachel, Volkmer Jens-Peter, Ho Po Yi, McKenna Kelly M, Cheshier Samuel, Zhang Michael, Guo Nan, Gip Phung, Mitra Siddhartha S, Weissman Irving L

机构信息

Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford Cancer Institute, and.

Institute for Stem Cell Biology and Regenerative Medicine.

出版信息

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2145-50. doi: 10.1073/pnas.1424907112. Epub 2015 Feb 2.

Abstract

Macrophage-mediated programmed cell removal (PrCR) is an important mechanism of eliminating diseased and damaged cells before programmed cell death. The induction of PrCR by eat-me signals on tumor cells is countered by don't-eat-me signals such as CD47, which binds macrophage signal-regulatory protein α to inhibit phagocytosis. Blockade of CD47 on tumor cells leads to phagocytosis by macrophages. Here we demonstrate that the activation of Toll-like receptor (TLR) signaling pathways in macrophages synergizes with blocking CD47 on tumor cells to enhance PrCR. Bruton's tyrosine kinase (Btk) mediates TLR signaling in macrophages. Calreticulin, previously shown to be an eat-me signal on cancer cells, is activated in macrophages for secretion and cell-surface exposure by TLR and Btk to target cancer cells for phagocytosis, even if the cancer cells themselves do not express calreticulin.

摘要

巨噬细胞介导的程序性细胞清除(PrCR)是在程序性细胞死亡之前清除病变和受损细胞的重要机制。肿瘤细胞上的“吃掉我”信号诱导PrCR,而诸如CD47等“别吃我”信号则会与之抗衡,CD47与巨噬细胞信号调节蛋白α结合以抑制吞噬作用。阻断肿瘤细胞上的CD47会导致巨噬细胞的吞噬作用。在这里,我们证明巨噬细胞中Toll样受体(TLR)信号通路的激活与阻断肿瘤细胞上的CD47协同作用,以增强PrCR。布鲁顿酪氨酸激酶(Btk)介导巨噬细胞中的TLR信号传导。钙网蛋白先前被证明是癌细胞上的“吃掉我”信号,在巨噬细胞中被TLR和Btk激活以进行分泌和细胞表面暴露,从而靶向癌细胞进行吞噬,即使癌细胞本身不表达钙网蛋白。

相似文献

1
Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk.
Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2145-50. doi: 10.1073/pnas.1424907112. Epub 2015 Feb 2.
2
Bruton's tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin.
J Immunol. 2013 May 15;190(10):5207-15. doi: 10.4049/jimmunol.1300057. Epub 2013 Apr 17.
3
Modulating macrophage-mediated programmed cell removal: An attractive strategy for cancer therapy.
Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189172. doi: 10.1016/j.bbcan.2024.189172. Epub 2024 Aug 14.
4
Bruton's tyrosine kinase is required for TLR-induced IL-10 production.
J Immunol. 2006 Nov 15;177(10):7203-10. doi: 10.4049/jimmunol.177.10.7203.
6
Bruton's tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages.
J Immunol. 2011 Jul 15;187(2):817-27. doi: 10.4049/jimmunol.1003631. Epub 2011 Jun 15.
7
Bruton's tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells.
Cell Signal. 2009 Jan;21(1):79-86. doi: 10.1016/j.cellsig.2008.09.010. Epub 2008 Sep 26.
8
Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy.
ACS Nano. 2023 May 23;17(10):8966-8979. doi: 10.1021/acsnano.2c08240. Epub 2023 May 3.
9
CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis.
Immunity. 2020 Aug 18;53(2):290-302.e6. doi: 10.1016/j.immuni.2020.07.008. Epub 2020 Aug 7.
10
Nanoparticle-Enabled Dual Modulation of Phagocytic Signals to Improve Macrophage-Mediated Cancer Immunotherapy.
Small. 2020 Nov;16(46):e2004240. doi: 10.1002/smll.202004240. Epub 2020 Oct 26.

引用本文的文献

1
SMAC mimetics induce human macrophages to phagocytose live cancer cells.
Immunother Adv. 2025 Jul 9;5(1):ltaf026. doi: 10.1093/immadv/ltaf026. eCollection 2025.
2
How macrophages use extracellular calreticulin to chase their prey.
Oncoimmunology. 2025 Dec;14(1):2533494. doi: 10.1080/2162402X.2025.2533494. Epub 2025 Jul 12.
3
Macrophage activation determines muscle wasting in pancreatic cancer.
Oncogene. 2025 May 29. doi: 10.1038/s41388-025-03434-9.
4
Macrophages release neuraminidase and cleaved calreticulin for programmed cell removal.
Proc Natl Acad Sci U S A. 2025 May 27;122(21):e2426644122. doi: 10.1073/pnas.2426644122. Epub 2025 May 21.
5
Metal-based immunogenic cell death inducers for cancer immunotherapy.
Chem Sci. 2025 Feb 25;16(15):6160-6187. doi: 10.1039/d4sc08495k. eCollection 2025 Apr 9.
7
Phosphoproteomic Profiling Reveals mTOR Signaling in Sustaining Macrophage Phagocytosis of Cancer Cells.
Cancers (Basel). 2024 Dec 19;16(24):4238. doi: 10.3390/cancers16244238.
8
Polyinosinic/Polycytidylic Lipid Nanoparticles Enhance Immune Cell Infiltration and Improve Survival in the Glioblastoma Mouse Model.
Mol Pharm. 2024 Dec 2;21(12):6339-6352. doi: 10.1021/acs.molpharmaceut.4c00875. Epub 2024 Nov 18.
10
Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond.
Curr Issues Mol Biol. 2024 Jul 23;46(8):7795-7811. doi: 10.3390/cimb46080462.

本文引用的文献

3
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8. doi: 10.1073/pnas.1305569110. Epub 2013 May 20.
4
The history of Toll-like receptors - redefining innate immunity.
Nat Rev Immunol. 2013 Jun;13(6):453-60. doi: 10.1038/nri3446. Epub 2013 May 17.
5
Bruton's tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin.
J Immunol. 2013 May 15;190(10):5207-15. doi: 10.4049/jimmunol.1300057. Epub 2013 Apr 17.
6
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
Leuk Lymphoma. 2013 Nov;54(11):2385-91. doi: 10.3109/10428194.2013.777837. Epub 2013 Aug 28.
7
Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.
Curr Hematol Malig Rep. 2013 Mar;8(1):1-6. doi: 10.1007/s11899-012-0147-9.
8
Toll-like receptor signaling.
Cold Spring Harb Perspect Biol. 2013 Jan 1;5(1):a011247. doi: 10.1101/cshperspect.a011247.
9
Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.
J Exp Med. 2012 Sep 24;209(10):1883-99. doi: 10.1084/jem.20120502. Epub 2012 Sep 3.
10
Anticancer TLR agonists on the ropes.
Nat Rev Drug Discov. 2012 Jun 29;11(7):503-5. doi: 10.1038/nrd3775.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验